The results of recent trials showed that after 24 months, 12.5% to 45% of newly diagnosed GBM patients were still alive, e.g., 12.5% of patients with unmethylated O-6-methylguanine-DNA methyltransferase (MGMT) promoters treated with cilengitide in addition to SOC [2], as compared to 45% of patients with methylated MGMT promoter [3]. The gene discussed is MGMT; the disease is glioblastoma.